Stock of the Day - February 22, 2021

Fresenius Medical Care AG & Co. KGaA (FMS)

$22.11

+$0.57 (+2.6%)

Market Cap: $11.57B

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Today's Trend

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported a mixed second quarter, and its stock price has decreased as investors focused more on weakening U.S. dialysis volumes and unchanged full-year guidance than on the earnings beat.

Second-quarter adjusted earnings came in at $0.66 per share, above the $0.62 analyst consensus, while revenue of $5.55 billion also exceeded expectations of $5.49 billion. Cost reductions and favorable U.S. reimbursement rates supported profitability. Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Management’s revenue outlook is reported at approximately $23.8 billion, above the roughly $22.9 billion consensus estimate, indicating expectations for continued top-line resilience. Fresenius Medical Care quarterly earnings results
Fresenius Medical Care reaffirmed its full-year 2026 outlook rather than raising it. This preserves management’s expectations but fell short of investors looking for an upgrade after the quarterly earnings beat. Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
U.S. treatment volumes declined again in the second quarter, raising concerns about patient growth and the sustainability of operating gains. The volume weakness overshadowed the profit beat and remains the main reason investors are selling FMS shares. Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further

The earnings call is likely to provide additional detail on volume trends, cost savings, reimbursement conditions and the path to achieving the 2026 outlook. Fresenius Medical Care Q2 2026 Earnings Call Transcript

← Previous Stock of the Day Next Stock of the Day →